Abstract
Treatment of chronic hepatitis C (HCV) was based on Interferon alpha IFNa administration three times a week (tiw), but the efficacy of this schedule (evaluated as virological sustained response) was limited to less than 20% of patients. The combination of Ribavirin and IFN is known to be significantly more effective than IFN monotherapy in naive and relapser patients but it induces a sustained response only in 41% of patients and in less than 30% of patients infected with genotype 1. Several studies on IFN and viral kinetics suggested that daily administration of IFN may increase the sustained response rate. The development of pegylated IFNs, characterized by a long half life and weekly administrability, seems to induce a significant improvement in the treatment of chronic hepatitis particularly in combination with Ribavirin. In order to further improve the efficacy of treatment in chronic hepatitis C (HCV) many controlled clinical trials evaluating Amantadine, Micophenolate, a1 Thymosin, Maxamine (in combination with IFN or pegylated IFN), Protease, Helicase, Polymerase inhibitors, Ribozymes and anti-sense olygonucleotides, and Interleukin 10 are in progress. Finally anti-HCV vaccine development seems to be very promising.
Keywords: hepatitis c, ifnx, viral kinetics, hcv, anti-hcv, pegylated interferon
Current Pharmaceutical Design
Title: New Therapies for the Treatment of Chronic Hepatitis C
Volume: 8 Issue: 11
Author(s): G. Ideo and A. Bellobuono
Affiliation:
Keywords: hepatitis c, ifnx, viral kinetics, hcv, anti-hcv, pegylated interferon
Abstract: Treatment of chronic hepatitis C (HCV) was based on Interferon alpha IFNa administration three times a week (tiw), but the efficacy of this schedule (evaluated as virological sustained response) was limited to less than 20% of patients. The combination of Ribavirin and IFN is known to be significantly more effective than IFN monotherapy in naive and relapser patients but it induces a sustained response only in 41% of patients and in less than 30% of patients infected with genotype 1. Several studies on IFN and viral kinetics suggested that daily administration of IFN may increase the sustained response rate. The development of pegylated IFNs, characterized by a long half life and weekly administrability, seems to induce a significant improvement in the treatment of chronic hepatitis particularly in combination with Ribavirin. In order to further improve the efficacy of treatment in chronic hepatitis C (HCV) many controlled clinical trials evaluating Amantadine, Micophenolate, a1 Thymosin, Maxamine (in combination with IFN or pegylated IFN), Protease, Helicase, Polymerase inhibitors, Ribozymes and anti-sense olygonucleotides, and Interleukin 10 are in progress. Finally anti-HCV vaccine development seems to be very promising.
Export Options
About this article
Cite this article as:
Ideo G. and Bellobuono A., New Therapies for the Treatment of Chronic Hepatitis C, Current Pharmaceutical Design 2002; 8 (11) . https://dx.doi.org/10.2174/1381612024607009
DOI https://dx.doi.org/10.2174/1381612024607009 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Clinical Significance of the New Cardiovascular Risk Markers in Diabetes Mellitus
Current Diabetes Reviews Recent Advances in Chemical Genomics
Current Medicinal Chemistry Dietary Carbohydrates that Modulate the Immune System
Clinical Immunology, Endocrine & Metabolic Drugs (Discontinued) Effective Delivery Routes and Strategies for Solid Lipid Nanoparticles (SLN) and Nanostructured Lipid Carriers (NLC)
Current Pharmaceutical Design Endothelin and Oxidative Stress in the Vascular System
Current Vascular Pharmacology Strategies for the Biological Evaluation of Gold Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Hormones and their Receptors Bridge Fat and Bone Metabolisms
Current Signal Transduction Therapy Preventing Atherosclerosis with Angiotensin-Converting Enzyme Inhibitors: Emphasis on Diabetic Atherosclerosis
Current Drug Targets - Cardiovascular & Hematological Disorders Inflammasome, Inflammation and Cancer: An Interrelated Pathobiological Triad
Current Drug Targets Current Advances in Delivery of Biotherapeutics Across the Blood-Brain Barrier
Current Drug Discovery Technologies Single-Cell Sequencing for Drug Discovery and Drug Development
Current Topics in Medicinal Chemistry Berberine Administration in Treatment of Colitis: A Review
Current Drug Targets Intrinsic Properties of Mesemchymal Stem Cells from Human Bone Marrow, Umbilical Cord and Umbilical Cord Blood Comparing the Different Sources of MSC
Current Stem Cell Research & Therapy Obstructive Sleep Apnea in Chronic Obstructive Pulmonary Disease: The Overlap Syndrome
Current Respiratory Medicine Reviews Effect of miRNAs, Proinflammatory Cytokines and ACE2 in COVID-19 Pathophysiology
Coronaviruses Toxicity of Nanoparticles
Current Medicinal Chemistry Antibiotics and Non-Steroidal Anti-Inflammatory Drugs in Outpatient Practice: Indications and Unwanted Effects in a Gastroenterological Setting
Current Drug Safety The BET-Bromodomain Inhibitor JQ1 Reduces Inflammation and Tau Phosphorylation at Ser396 in the Brain of the 3xTg Model of Alzheimer’s Disease
Current Alzheimer Research Invited Editorial: MERS-CoV An Emerging Viral Zoonotic Disease: Three Years After and Counting
Recent Patents on Anti-Infective Drug Discovery Endocrine Therapy of Breast Cancer
Current Medicinal Chemistry